Solstice Biologics Names CEO With Boston VC PedigreeMonday, June 9, 2014
San Diego startup Solstice Biologics LLC has lured Boston venture capitalist Lou Tartaglia to become its new president and CEO.
Solstice, founded in 2012, is funded with $18 million in Series A funding from venBio and Aeris Capital AG. It is working on RNA interference technology licensed from the University of California, San Diego.
Tartaglia has worked in biotech for more than 20 years, most recently as a partner at Third Rock Ventures in Boston — one of the most active life sciences venture firms in the country He has also worked in leadership positions at GeneLogic Inc. and Millennium Pharmaceuticals Inc., and has worked at Genentech Inc.
Solstice also appointed its financial adviser, John Borgeson, to be its chief financial officer. Borgeson hails from Pfizer Inc., having spent 20 years as part of its financial leadership team.